Difference between revisions of "Metoclopramide (Reglan)"
m |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
||
| Line 18: | Line 18: | ||
[[Category:Dopamine receptor antagonist]] | [[Category:Dopamine receptor antagonist]] | ||
| − | [[Category: | + | [[Category:FDA approved in 1980]] |
[[Category:WHO Essential Pain and Palliative Care Medicine]] | [[Category:WHO Essential Pain and Palliative Care Medicine]] | ||
Revision as of 19:10, 30 July 2018
General information
Class/mechanism: Antiemetic; The antiemetic action of metoclopramide is due to its antagonist activity at D2 receptors in the chemoreceptor trigger zone (CTZ)
Route: PO/IV
Extravasation: unknown
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
No known antineoplastic properties. Used for treatment and/or prevention of chemotherapy-induced nausea & vomiting.
Also known as
- Brand name: Reglan